Literature DB >> 1070015

Bioenergetics in clinical medicine: prevention by forms of coenzyme Q of the inhibition by adriamycin of coenzyme Q10-enzymes in mitochondria of the myocardium.

T Kishi, T Watanabe, K Folkers.   

Abstract

Adriamycin inhibits the succinoxidase system and the NADH-oxidase system. Both of the intact mitocondrial enzymes and the pentane-extracted preparations are inhibited. The inhibition can be prevented by a molar ratio of coenzyme to adriamycin of 3:1 for coenzyme Q10 (ubiquinone), 5:1 for coenzyme Q7, and 5:1 for coenzyme Q4. Prevention of inhibition was observed in the decreasing order of coenzyme Q10 greater than coenzyme Q7 greater than H6 coenzyme Q4 greater than coenzyme Q4. Adriamycinone was three times more inhibitory than adriamycin, which is compatible with a less polar fragment necessary to inhibit the lipoidal coenzyme Q10. Daunomycinone was not inhibitory at a concentration at which adriamycinone is effective, indicating that the hydroxyl group of the latter could be binding at the receptor, since it should not influence electron transfer or rings B and C.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 1070015      PMCID: PMC431583          DOI: 10.1073/pnas.73.12.4653

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  13 in total

1.  Letter: Prevention by coenzyme Q10 (NSC-140865) of the inhibition by adriamycin (NSC-123127) of coenzyme Q10 enzymes.

Authors:  T Kishi; K Folkers
Journal:  Cancer Treat Rep       Date:  1976-03

2.  Protein measurement with the Folin phenol reagent.

Authors:  O H LOWRY; N J ROSEBROUGH; A L FARR; R J RANDALL
Journal:  J Biol Chem       Date:  1951-11       Impact factor: 5.157

3.  Antimetabolites of coenzyme Q. XV. Inhibition of mitochondrial reductase systems by naphthoquinone and quinolinequinone analogs.

Authors:  F S Skelton; T H Porter; G P Littarru; K Folkers
Journal:  Int J Vitam Nutr Res       Date:  1973       Impact factor: 1.784

4.  Apparent low levels of ubiquinone in rat and human neoplastic tissues.

Authors:  M Shichiri; Y Shigeta; H Abe; K Izumi; E Redalieu; K Folkers
Journal:  Int Z Vitaminforsch       Date:  1968

5.  Effects of anticancer agents on the respiration of isolated mitochondria and tumor cells.

Authors:  M Gosalvez; M Blanco; J Hunter; M Miko; B Chance
Journal:  Eur J Cancer       Date:  1974-09       Impact factor: 9.162

6.  Deficiency of coenzyme Q 10 in human heart disease. II.

Authors:  G P Littarru; L Ho; K Folkers
Journal:  Int J Vitam Nutr Res       Date:  1972       Impact factor: 1.784

7.  The potential of coenzyme Q 10 (NSC-140865) in cancer treatment.

Authors:  K Folkers
Journal:  Cancer Chemother Rep 2       Date:  1974-12

8.  Synthesis and bioassays of a new dimethoxyalkylmercapto-1,4-benzoquinones.

Authors:  R J Wikholm; Y Iwamoto; C B Bogentoft; T H Porter; K Folkers
Journal:  J Med Chem       Date:  1974-08       Impact factor: 7.446

9.  Inhibition of coenzyme Q10-enzymes, succinoxidase and NADH-oxidase, by adriamycin and other quinones having antitumor activity.

Authors:  Y Iwamoto; I L Hansen; T H Porter; K Folkers
Journal:  Biochem Biophys Res Commun       Date:  1974-06-04       Impact factor: 3.575

10.  Bioenergetics in clinical medicine. III. Inhibition of coenzyme Q10-enzymes by clinically used anti-hypertensive drugs.

Authors:  H Kishi; T Kishi; K Folkers
Journal:  Res Commun Chem Pathol Pharmacol       Date:  1975-11
View more
  8 in total

1.  Detection of doxorubicin cardiotoxicity by using iodine-123 BMIPP early dynamic SPECT: quantitative evaluation of early abnormality of fatty acid metabolism with the Rutland method.

Authors:  K Saito; K Takeda; S Okamoto; R Okamoto; K Makino; Y Tameda; Y Nomura; H Maeda; T Ichihara; T Nakano
Journal:  J Nucl Cardiol       Date:  2000 Nov-Dec       Impact factor: 5.952

2.  Covalent protein binding of reactive adriamycin metabolites in rat liver and rat heart microsomes.

Authors:  M E Scheulen; H Kappus; A Nienhaus; C G Schmidt
Journal:  J Cancer Res Clin Oncol       Date:  1982       Impact factor: 4.553

Review 3.  The contribution of the cholesterol biosynthetic pathway to intermediary metabolism and cell function.

Authors:  R Fears
Journal:  Biochem J       Date:  1981-10-01       Impact factor: 3.857

4.  Rescue by coenzyme Q10 from electrocardiographic abnormalities caused by the toxicity of adriamycin in the rat.

Authors:  K Folkers; J Y Choe; A B Combs
Journal:  Proc Natl Acad Sci U S A       Date:  1978-10       Impact factor: 11.205

5.  Detection of adriamycin-induced cardiotoxicity in cultured heart cells with technetium 99m-SESTAMIBI.

Authors:  D Piwnica-Worms; M L Chiu; J F Kronauge
Journal:  Cancer Chemother Pharmacol       Date:  1993       Impact factor: 3.333

Review 6.  Doxorubicin (adriamycin) cardiomyopathy.

Authors:  E Saltiel; W McGuire
Journal:  West J Med       Date:  1983-09

7.  Resistance to adriamycin cytotoxicity among respiratory-deficient mutants in yeast.

Authors:  S C Hixon; A Ocak; J E Thomas; J P Daugherty
Journal:  Antimicrob Agents Chemother       Date:  1980-03       Impact factor: 5.191

Review 8.  Role of Mitophagy in Coronary Heart Disease: Targeting the Mitochondrial Dysfunction and Inflammatory Regulation.

Authors:  Mingxuan Liu; Ying Wu
Journal:  Front Cardiovasc Med       Date:  2022-02-04
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.